A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection.

ABSTRACT:

Background

Data from studies in nonhuman primates suggest that the triple monoclonal antibody cocktail ZMapp is a promising immune-based treatment for Ebola virus disease (EVD).

Methods

Beginning in March 2015, we conducted a randomized, controlled trial of ZMapp plus the current standard of care as compared with the current standard of care alone in patients with EVD that was diagnosed in West Africa by polymerase-chain-reaction (PCR) assay. Eligible patients of any age were randomly assigned in a 1:1 ratio to receive either the current standard of care or the current standard of care plus three intravenous infusions of ZMapp (50 mg per kilogram of body weight, administered every third day). Patients were stratified according to baseline PCR cycle-threshold value for the vi

SUBMITTER: PREVAIL II Writing Group 

PROVIDER: S-EPMC5086427 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature